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Abstract
Background: Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for coronary artery disease 
(CAD). However, its role in real-world practice and implications for clinical care remains limited. 
Under investigation herein, are the clinical characteristics associated with increased Lp(a) levels in 
patients presenting with acute coronary syndrome (ACS).
Methods: Lp(a) was measured at admission in patients ≤ 65 years of age presenting with ACS in  
a single center. Logistic regression model was used to determine the independent association of clinical 
characteristics with elevated Lp(a). 
Results: A total of 134 patients were screened for Lp(a); 83% males, mean age 52 ± 8 years. Median 
Lp(a) level was 46 nmol/L (interquartile range [IQR] 13–91). Elevated Lp(a) > 72 nmol/L (30 mg/dL) 
was documented in 32% and associated with younger age at CAD diagnosis. In a multiple logistic regres-
sion model, premature CAD (odds ratio [OR] 3.85, 95% confidence interval [CI] 1.48–10.07, p = 0.06),  
previous revascularization (OR 2.56, 95% CI 1.17–5.59, p = 0.019) and probable/definite familial 
hypercholesterolemia (FH) (OR 3.18, 95% CI 1.10–9.21, p = 0.033), were independently associated 
with elevated Lp(a). In contrast, Lp(a) levels were not associated with other traditional cardiovascular 
risk factors, previous statin treatment, C-reactive protein level or ACS type.  
Conclusions: In young and middle-aged patients presenting with ACS, premature CAD, previous re-
vascularization and FH were independently associated with elevated Lp(a), indicating progressive CAD 
and higher cardiovascular risk. These results, are in accordance with guideline based recommendations 
for Lp(a) screening, and may be of importance in addressing residual cardiovascular risk in young 
ACS patients, in light of the novel emerging therapies targeting Lp(a). (Cardiol J 2019; 26, 5: 511–518)
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Introduction
Lipoprotein(a) [Lp(a)] consists of an apolipo-
protein B containing low-density lipoprotein (LDL) 
like particle, covalently linked to plasminogen-like 
glycoprotein apo(a) [1]. Lp(a) is mainly determined 
genetically by the LPA gene, and is considered 
proatherogenic, proinflammatory and potentially 
antifibrinolytic [2]. Evidence from epidemiological 
and clinical analyses in both primary and secondary 
prevention populations show an independent asso-
ciation between Lp(a) and risk for cardiovascular dis-
ease (CVD) and death [3–8], results that are further 
supported by genetic studies indicating that Lp(a) 
has a causal role in the development of coronary 
artery disease (CAD) [9–11]. Nevertheless, despite 
these associations, the value of Lp(a) as a prognostic 
biomarker remains controversial and is incompletely 
defined due to lack of standardized assays [12], the 
limited therapeutic options for significantly lower-
ing Lp(a) and the need of outcome data showing the 
benefit of lowering Lp(a) levels [13].
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Although screening for Lp(a) is recommended 
by professional societies in selected patients [14], 
there is wide variation in the clinical utility of 
Lp(a) measurement among health care provid-
ers, and real-life data regarding the screening for 
Lp(a) levels in patients with established CAD is 
limited. It is therefore important to identify clini-
cal characteristics and risk factors associated with 
elevated Lp(a), as well as high-risk populations in 
whom future preventive strategies and emerging 
therapies will be applied [15]. In addition, screen-
ing for Lp(a) in the younger population presenting 
with acute coronary syndrome (ACS) may serve as 
an opportunity to identify residual cardiovascular 
risk, with long-term implications. 
In light of these considerations, the aim of the 
current study was to investigate the clinical fea-
tures associated with elevated Lp(a) in young and 
middle-aged patients ≤ 65 years presenting with 
ACS. Moreover, as Lp(a) levels were suggested 
to be related to pro-inflammatory conditions  [16, 
17], their association with C-reactive protein (CRP) 
levels at presentation with ACS will be analyzed. 
Methods
Study design
This study is a retrospective observational 
cohort analysis performed in a single center at 
Lady Davis Carmel Medical Center, Haifa, Israel. 
134 patients were included, aged 65 years and un-
der who presented to the Cardiology Department 
with ACS between June 2016 to November 2017 
and were tested for Lp(a) levels. Blood analysis 
was performed at a single laboratory with sam-
ples collected within 24 h of hospital admission. 
Laboratory blood tests included Lp(a) levels, 
routine lipid panel, kidney function tests and 
CRP levels. LDL cholesterol was calculated by 
the Friedwald formula. Lp(a) was measured using 
a particle-enhanced quantitative turbidimetric im-
munoassay (PETIA) (Tina-quant® Lipoprotein (a) 
Gen.2, Roche Diagnostics International Ltd.), on 
a COBAS automated chemistry analyzer. Lp(a) levels 
were reported in nmol/L units, according to recent 
recommendations [13]. Levels above 72 nmol/L 
were considered elevated (estimated conversion 
factor from molar to mass based concentration: 
1 nmol/L × 0.4167 = mg/dL), consistent with tradi-
tional thresholds for elevated Lp(a) above 30 mg/dL 
which approximate the 75th percentile in white 
populations, and also reflect epidemiological data 
of CVD risk thresholds [4, 18]. 
Additional demographic and clinical charac-
teristics as well as traditional cardiovascular risk 
factors were recorded from computerized data of 
patient files. Patients were assessed for clinical 
indications to Lp(a) measurement, as recom-
mended by customary guidelines [14], including 
(1) premature CAD (male age < 55 years and female 
age < 60 years), (2) family history of premature 
CAD, (3) familial hypercholesterolemia (FH) and 
(4) markers of progressive CAD including previous 
revascularization, presence of multi-vessel CAD 
and need for cardiac surgery. The clinical diagnosis 
of FH was established using the Dutch Lipid Clinic 
Network (DLCN) algorithm [19]. Peak LDL cho-
lesterol level documented in each patient’s history 
was used to calculate the DLCN score. FH was 
considered probable or definite if the total score 
was ≥ 6 points. The study was approved by the 
Lady Davis Carmel Medical Center Institutional 
Ethics Committee in Haifa, Israel, with a waiving 
of the need for individual patient consent.
Data analysis
Continuous data are presented as means ± 
± standard deviation or median and interquartile 
range (IQR), and categorical variables as num-
bers and percentages. The independent-samples 
T-test or Mann-Whitney test was used to compare 
continuous variables and the c2 test to compare 
categorical variables. The Fisher exact test was 
used in cases of small sample size. Information on 
covariates was complete except for CRP levels, 
missing in 3 patients. Spearman’s correlation co-
efficient was used to investigate the relationship 
between Lp(a) and CRP levels at admission.
Multivariate logistic regression model was 
used to determine the independent association 
between clinical characteristics and elevated Lp(a), 
defined as > 72 nmol/L. Included in the multivari-
able model were variables with a significance level 
< 0.20 in the univariate analysis. Odds ratio were 
further adjusted for age, gender and statin treat-
ment prior to hospitalization. Lp(a) levels were 
additionally analyzed according to distribution into 
tertiles. The results were considered statistically 
significant when the 2-sided p-value was < 0.05. 
SPSS statistical software version 20.0 was used to 
perform all statistical analyses.
Results
Lipoprotein(a) was measured in 134 patients 
aged 65 years and under presenting with ACS. Un-
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stable angina was diagnosed in 11% of the patients, 
non ST-segment elevation myocardial infarction 
(NSTEMI) in 58%, and ST-segment elevation myo-
cardial infarction (STEMI) in 31%. Mean age was 
52 ± 8 years and 83% were males. Mean LDL choles-
terol level at admission with ACS was 123 ± 52 mg/ 
/dL, and high-density lipoprotein (HDL) cholesterol 
35 ± 9 mg/dL. Median Lp(a) level was 46 (IQR 13–91) 
nmol/L. Lp(a) level distribution in the study popula-
tion is presented in Figure 1, showing a skewed 
distribution with a tail towards the highest levels. 
Younger patients under 45 years of age (n = 24) had 
significantly higher Lp(a) levels than middle-aged 
patients between 45 and 65 years (n = 110): mean 
105 ± 119 nmol/L, median (IQR) 61 (24–120) nmol/L 
vs. mean 65 ± 70 nmol/L, median (IQR) 40 (11–83) 
nmol/L, p = 0.027, respectively. Similarly, their mean 
LDL-cholesterol levels were higher: 143 ± 66 mg/dL 
vs. 119 ± 48 mg/dL, p = 0.037, respectively.
Elevated Lp(a) > 72 nmol/L was documented 
in 43 patients with ACS (32%) and associated with 
younger age and premature CAD (men < 55 years 
and women < 60 years) (Table 1). In addition, 
elevated Lp(a) was associated with previous re-
vascularization (42% vs. 22%, p = 0.017) and more 
prevalent clinical diagnosis of probable/definite FH 
(21% vs. 8%, p = 0.027). In contrast, elevated Lp(a) 
was not related to other traditional risk factors such 
as hypertension, diabetes, smoking, chronic kidney 
disease, as well as family history of premature 
CAD; nor was it associated with previous statin 
treatment or ACS type (Table 1). Triglyceride and 
cholesterol levels at admission were comparable in 
both Lp(a) groups. In addition, performance rates of 
cardiac surgery and angiographic evidence of 3 ves-
sel CAD were also similar between patients with 
and without elevated Lp(a) levels. In a multiple lo-
gistic regression model, previous revascularization, 
premature CAD and probable/definite FH remained 
independently and significantly associated with 
high Lp(a) levels, after additional adjustment to 
age, gender and previous statin therapy (Table 2). 
These independent risk markers of progressive 
CAD were also associated with Lp(a) levels strati-
fied by tertiles (Fig. 2). Moreover, an increase in 
20 nmol/L in Lp(a) was associated with significant 
increase in the adjusted odds ratio (OR) for pre-
mature CAD (OR 1.237, 95% confidence interval 
[CI] 1.014–1.509, p = 0.036), but not the other two 
risk predictors.
C-reactive protein levels measured at admis-
sion of patients with ACS were not correlated with 
elevated Lp(a), both when analyzed as a continuous 
variable (Spearman’s correlation coefficient 0.136, 
p = 0.120) or as a categorical variable (high CRP 
levels observed in 27% of those with elevated Lp(a) 
compared to 23% with normal Lp(a), p = 0.630). 
Repeat Lp(a) was measured ≥ 2 months after 
discharge in 5 patients with significantly high ad-
mission Lp(a) levels, and remained elevated in all 
subjects (Fig. 3).
Discussion
In the present study of patients presenting 
with ACS, elevated Lp(a) was evident in a third of 
the population and was associated with younger 
age, premature CAD and previous revascularization 
indicating progressive CAD. Furthermore, high 
Lp(a) was related to clinical diagnosis of probable/
0
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Figure 1. Lipoprotein(a) level distribution in study population.
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definite FH. In contrast, traditional cardiovascular 
risk factors were not associated with elevated 
Lp(a), and no correlation was observed between 
admission CRP levels during ACS and Lp(a).
Plasma levels of Lp(a) are similar in men and 
women and show a skewed distribution in the popu-
lation with a tail towards the highest levels. Lp(a) 
concentration is lower in non-Hispanic Caucasians 
and Asian populations, and higher in Hispanic and 
Black ethnic populations [18]. Individual studies 
used different thresholds to define elevated Lp(a), 
with common thresholds of 30 mg/dL and 50 mg/dL, 
corresponding to the 75th and 80th percentiles in the 
general population. In the setting of a large referral 
center, Lp(a) levels > 30 mg/dL and > 50 mg/dL 
were shown to be fairly common, present in 35% 
and 24% of the subjects, respectively [20]. This is 
in line with the current study, in which 32% of the 
patients presenting with ACS at a relatively young 
age had Lp(a) levels above a cutoff equivalent to 
30 mg/dL. 
Although there is an exponential relationship 
between Lp(a) levels and cardiovascular risk, in 
epidemiological and Mendelian randomization stud-
ies increased cardiovascular risk starts at a level 
as low as 20 mg/dL or 50 nmol/L, especially when 
Table 1. Patient characteristics according to lipoprotein(a) [Lp(a)] level.
Variable Total  
(n = 134)
Lp(a) < 72 nmol/L  
(n = 91)
Lp(a) > 72 nmol/L  
(n = 43)
P 
Age [years] (range 29–65) 52.2 ± 8.0 53.1 ± 7.8 50.3 ± 8.3 0.056
Age at CAD diagnosis 49.9 ± 9.0 51.3 ± 8.9 47.1 ± 8.6 0.010
Gender (male) 111 (83%) 75 (82%) 36 (84%) 0.852
Family history of premature CAD 75 (56%) 51 (56%) 24 (54%) 0.980
Dyslipidemia 100 (75%) 69 (76%) 31 (72%) 0.643
Hypertension  71 (53%) 46 (51%) 25 (58%) 0.411
Diabetes mellitus 42 (31%) 27 (30%) 15 (35%) 0.544
Obesity (BMI > 30 kg/m2) 51 (39%) 397 (43%) 12 (29%) 0.105
Current smoking 69 (52%) 51 (56%) 18 (42%) 0.125
Chronic kidney disease 13 (10%) 7 (8%) 6 (14%) 0.348
Stroke 5 (4%) 4 (4%) 1 (2%) 0.484
Previous revascularization 38 (28%) 20 (22%) 18 (42%) 0.017
LDL cholesterol [mg/dL] 123 ± 520 123 ± 520 124 ± 520 0.909
Triglycerides [mg/dL] 225 ± 218 223 ± 201 228 ± 251 0.902
HDL cholesterol [mg/dL] 35 ± 90 34 ± 90 37 ± 10 0.116
Peak LDL cholesterol [mg/dL] 165 ± 460 163 ± 470 171 ± 440 0.364
Probable/definite FH 16 (12%) 7 (8%) 9 (21%) 0.027
Previous statin therapy 65 (49%) 41 (45%) 24 (56%) 0.245
Cardiac surgery 23 (17%) 16 (17%) 7 (16%) 0.341
Unstable angina 15 (11%) 8 (9%) 7 (16%)
NSTEMI 77 (58%) 55 (60%) 22 (51%) 0.381
STEMI 42 (31%) 28 (31%) 14 (33%)  
Three-vessel CAD 53 (40%) 35 (39%) 18 (42%) 0.707
Premature CAD 93 (69%) 56 (61%) 37 (86%) 0.004
BMI — body mass index; CAD — coronary artery disease; FH — familial hypercholesterolemia; HDL — high-density lipoprotein; LDL — low-
-density lipoprotein; NSTEMI — non-ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial infarction
Table 2. Multivariate regression analysis showing 
independent associations between clinical  
characteristics and elevated lipoprotein(a)*.
Variable Odds ratio 95% CI P 
Previous  
revascularization
2.56 1.17–5.59 0.019
Premature CAD 3.85 1.48–10.07 0.06
Probable/definite FH 3.18 1.10–9.21 0.033
*Multivariable logistic regression model was adjusted to age,  
gender and previous statin therapy. CAD — coronary artery disease; 
CI — confidence interval; FH — familial hypercholesterolemia
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evaluated in primary care populations [10, 13, 18, 
21]. In the setting of ACS, there are non-conclusive 
findings. Past studies have demonstrated an as-
sociation between baseline Lp(a) concentrations 
and increased risk of cardiac death in patients 
admitted with ACS [22]. Lp(a) was also shown 
to be independently associated with ACS and 
subsequent cardiovascular events in younger and 
middle aged individuals below 60 years old [23–25]. 
However, data from sub-analyses of large prospec-
tive randomized trials of lipid-modifying therapies 
in patients with ACS or established CAD, showed 
conflicting results with some reporting no asso-
ciation between Lp(a) concentration and adverse 
cardiovascular outcomes [26–28], while others 
have demonstrated that Lp(a) was associated with 
increased cardiovascular risk [8, 29, 30]. Future 
studies with antisense oligonucleotides targeting 
apo(a), recently shown to reduce Lp(a) levels by 
80% in phase 2 trials, may further shed light on 
Figure 3. Admission versus post-hospitalization repeat lipoprotein(a) [Lp(a)] levels in 5 patients with acute coronary 
syndrome and elevated lipoprotein(a).
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the impact of Lp(a) reduction on cardiovascular 
outcomes in patients with CAD [15]. The present 
findings of a stepwise association between tertiles 
of Lp(a) with premature and progressive CAD 
support the role of Lp(a) as a risk marker also in 
patients with ACS. 
The European Society of Cardiology/European 
Atherosclerosis Society has given a Class IIa rec-
ommendation for measuring Lp(a) in patients with 
premature CVD, FH, family history of premature 
CVD or elevated Lp(a), as well as in those with 
recurrent CVD despite optimal lipid-lowering 
therapy, and also for risk reclassification in subjects 
with borderline risk [14]. Nevertheless, in many 
countries assays for Lp(a) measurement are not 
routinely available in clinical practice, often per-
formed only at dedicated lipid clinics, and there is 
low awareness for the risk associated with high 
Lp(a). Current results are consistent with the 
above recommendations, demonstrating an inde-
pendent association between the majority of these 
risk groups and high Lp(a) also in the setting of 
ACS. However, although the plasma level of Lp(a) 
is, to a major extent, genetically determined, no 
similar association was observed between Lp(a) 
and family history of premature CAD. This may 
have been affected by the use of an electronic chart 
diagnosis for defining positive family history and 
not by directly questioning the patients and prepar-
ing a family tree when appropriate.
Familial hypercholesterolemia is an autoso-
mal co-dominant genetic disorder associated with 
raised concentrations of LDL cholesterol from 
birth and an elevated risk of premature CVD [31]. 
Concentrations of Lp(a) are raised in patients with 
FH compared with individuals with normal lipid 
levels, and data in patients with FH shows that high 
Lp(a) levels further increase cardiovascular risk 
[32, 33]. Prospective data from 46,200 individuals 
from the Copenhagen General Population Study 
showed that the risk of myocardial infarction (MI) 
was highest in patients classified as having both FH 
and high Lp(a) values, concluding that high Lp(a) 
concentrations represent a novel risk factor for 
clinical FH, and suggesting that all individuals with 
FH should have their Lp(a) measured in order to 
identify those with the highest concentrations, and 
as a result, the highest risk for MI [34]. The present 
results, demonstrate that a clinical diagnosis of 
probable/definite FH is independently associated 
with elevated Lp(a) and premature CAD in patients 
presenting with ACS, are compatible with a recent 
investigation concluding that the combination of 
elevated Lp(a) and phenotypic FH is commonly 
encountered in patients with premature CAD 
admitted to the coronary care unit [35]. Overall, 
this data supports the routine screening for both 
FH and elevated Lp(a) in young patients hospital-
ized in cardiac units for evaluation or treatment 
of CAD. This will also serve as an opportunity to 
perform cascade-screening of relatives of identi-
fied index-cases, due to the genetic nature of both 
disorders [36]. 
Past small-scale studies have reported con-
flicting findings regarding the associations between 
Lp(a) levels and inflammatory markers following 
MI, with both increases or no change in Lp(a) 
levels as a function of increasing CRP levels [16, 
17, 37]. In patients with rheumatoid arthritis, high 
Lp(a) levels were related to an active inflammatory 
disease [38, 39]; while following an acute ischemic 
stroke, Lp(a) levels were shown to remain stable 
[40]. A more recent, far larger analysis, in the 
setting of the general population, reported only 
minimal increases in Lp(a) with increasing CRP 
levels [41]. Furthermore, the ability of elevated 
Lp(a) to predict ischemic heart disease and MI 
was not affected by markers of inflammation. In 
the current study, no correlation between CRP 
and Lp(a) concentration was found at admission of 
patients with ACS. In addition, in a small number of 
patients with significantly high Lp(a), repeat levels 
measured more than 2 months from the acute event 
remained high. These findings should be confirmed 
in larger studies, and could be clinically relevant, 
as Lp(a) measurement performed during the acute 
phase may lead to intensification of treatment such 
as with proprotein convertase subtilisin/kexin 
type 9 (PCSK9) monoclonal antibodies and pos-
sibly future apo(a) antisense therapy, in addition 
to a more aggressive management of modifiable 
cardiovascular risk factors [15].
Limitations of the study
Several limitations of the current study should 
be acknowledged. This is a retrospective analysis 
of a single center, with a relatively small sample 
size. Nevertheless, Lp(a) levels are not routinely 
measured in the study region, and there is low 
awareness of the health care providers to Lp(a) 
and its associated risk. In addition, as Lp(a) level 
varies among different races, and results may not 
be generalizable to other races or geographical 
areas. No genetic testing was performed for di-
agnosing FH, although a customary algorithm for 
phenotypically diagnosing probable and definite FH 
was used. Finally, it should be noted that theinde-
pendent associations between clinical variables 
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and Lp(a) levels described in this analysis do not 
prove causation.
Conclusions
In young and middle-aged patients ≤ 65 years 
of age presenting with ACS, previous revasculari-
zation, premature CAD and FH were independently 
associated with elevated Lp(a). These findings, 
limited by a small sample size, are in accordance 
with guideline based recommendations for Lp(a) 
screening, and suggest that testing for Lp(a) in 
young patients in the setting of ACS may address 
residual cardiovascular risk, with potential clinical 
benefit in light of the novel emerging therapies 
targeting Lp(a).
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